+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 1640292-55-2
1640292-55-2,MFCD25976611
Catalog No.:AA00AS0X

1640292-55-2 | Oclacitinib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98+%
in stock  
$11.00   $8.00
- +
5mg
98+%
in stock  
$23.00   $16.00
- +
10mg
98+%
in stock  
$33.00   $23.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00AS0X
Chemical Name:
Oclacitinib
CAS Number:
1640292-55-2
Molecular Formula:
C19H27N5O6S
Molecular Weight:
453.5126
MDL Number:
MFCD25976611
SMILES:
OC(=O)C=CC(=O)O.CNS(=O)(=O)CC1CCC(CC1)N(c1ncnc2c1cc[nH]2)C
Properties
Computed Properties
 
Complexity:
606  
Covalently-Bonded Unit Count:
2  
Heavy Atom Count:
31  
Hydrogen Bond Acceptor Count:
10  
Hydrogen Bond Donor Count:
4  
Rotatable Bond Count:
7  
Undefined Bond Stereocenter Count:
1  

Downstream Synthesis Route

[1]CurrentPatentAssignee:ZOETISINC.-US2017/233397,2017,A1

[1]CurrentPatentAssignee:ZOETISINC.-US2017/233397,2017,A1

[1]CurrentPatentAssignee:LIANYUNGANGYAHUIPHARMACHEM;CHANGZHOUYABANGQHPHARMACHEM;INNERMONGOLIAQIHUIPHARMACEUTICAL-CN112279854,2021,ALocationinpatent:Paragraph0064-0066;0083-0085

[2]CurrentPatentAssignee:ZOETISINC.-US2017/233397,2017,A1Locationinpatent:Paragraph0135

[3]CurrentPatentAssignee:ZHEJIANGJIUZHOUPHARMACEUTICALCO.,LTD.-CN107365312,2017,ALocationinpatent:Paragraph0102;0103

[1]CurrentPatentAssignee:ZOETISINC.-US2017/233397,2017,A1

CASUnavailable 
  1208319-27-0 

[1]CurrentPatentAssignee:ZOETISINC.-US2017/233397,2017,A1

Literature

Title: Gonzales AJ, et al. Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24.

Title: Fukuyama T, et al. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis. J Pharmacol Exp Ther. 2015 Sep;354(3):394-405.

Title: Cosgrove SB, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013 Oct;24(5):479-e114.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1640292-55-2
1208319-26-9

1208319-26-9

 2750534-84-8

2750534-84-8

 2750534-84-8

2750534-84-8
Building Blocks
More >
Tags:1640292-55-2 Molecular Formula|1640292-55-2 MDL|1640292-55-2 SMILES|1640292-55-2 Oclacitinib